Michael J. Labarre Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total value of $384,900.00. Following the sale, the senior vice president now owns 168,176 shares of the company’s stock, valued at $6,473,094.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $37.81 on Friday. The company has a market capitalization of $4.80 billion, a price-to-earnings ratio of 17.92, a PEG ratio of 0.46 and a beta of 1.25. Halozyme Therapeutics, Inc. has a twelve month low of $29.85 and a twelve month high of $45.00. The stock has a fifty day simple moving average of $39.50 and a 200 day simple moving average of $37.76. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 3.33 EPS for the current year.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of HALO. TD Asset Management Inc increased its holdings in Halozyme Therapeutics by 517.0% in the fourth quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock valued at $73,326,000 after purchasing an additional 1,662,390 shares during the period. Norges Bank acquired a new stake in Halozyme Therapeutics during the 4th quarter worth about $44,935,000. Epoch Investment Partners Inc. grew its holdings in Halozyme Therapeutics by 250.5% during the 4th quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock worth $42,986,000 after acquiring an additional 831,199 shares during the period. Macquarie Group Ltd. grew its holdings in Halozyme Therapeutics by 22.8% during the 1st quarter. Macquarie Group Ltd. now owns 3,200,481 shares of the biopharmaceutical company’s stock worth $122,226,000 after acquiring an additional 595,220 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its holdings in Halozyme Therapeutics by 174.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock worth $33,894,000 after acquiring an additional 563,989 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Benchmark restated a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday. Morgan Stanley dropped their price target on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating for the company in a research note on Tuesday, December 26th. The Goldman Sachs Group dropped their price target on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, January 18th. Finally, TheStreet cut Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $53.29.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.